Legacy Health System

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Activity

Key Events

Feb 10, 2026TrialImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking

Dec 12, 2024FDAZanaflex — ONTRALFY

Jan 7, 2021TrialSupracondylar Pinning Antibiotic Stewardship (SPAS) Trial

Jul 1, 2019TrialAcute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy

May 23, 2019TrialSafety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Jan 11, 2017FDAEsbriet — ESBRIET

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

14 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Esbriet3 patentsSep 22, 2026 Esbriet3 patentsDec 18, 2027 EsbrietMay 10, 2028 BetapaceAug 14, 2028 Esbriet4 patentsApr 22, 2029 Esbriet7 patentsJan 8, 2030 Naftin6 patentsJan 31, 2033 EsbrietAug 30, 2033

6 more

Betapace4 patentsApr 1, 2034 BetapaceAug 31, 2035 EsbrietMar 28, 2037 Betapace3 patentsAug 14, 2038 Betapace3 patentsApr 5, 2039 Zanaflex2 patentsMay 7, 2042

Regulatory

Regulatory Timeline

19822 events

FDAJan 1

Cloderm — CLODERM

Application NDA017765 (NDA)

FDAJan 1

Imuran — IMURAN

Application NDA016324 (NDA)

19851 event

FDAMay 24

Ridaura — RIDAURA

Application NDA018689 (NDA)

19882 events

FDAFeb 29

Naftin — NAFTIN

Application NDA019599 (NDA)

FDAFeb 29

Naftin — NAFTIN

Application NDA019599 (NDA)

19902 events

FDAJun 18

Naftin — NAFTIN

Application NDA019356 (NDA)

FDAJun 18

Naftin — NAFTIN

Application NDA019356 (NDA)

19921 event

FDAOct 30

Betapace — BETAPACE

Application NDA019865 (NDA)

19991 event

FDASep 10

Ethyol — ETHYOL

Application NDA020221 (NDA)

20001 event

FDAFeb 4

Zanaflex — ZANAFLEX

Application NDA020397 (NDA)

20021 event

FDAAug 29

Zanaflex — ZANAFLEX

Application NDA021447 (NDA)

20032 events

FDADec 23

Lotronex — LOTRONEX

Application NDA021107 (NDA)

FDAApr 2

Betapace — BETAPACE AF

Application NDA021151 (NDA)

20091 event

FDAJul 2

Betapace — SOTALOL HYDROCHLORIDE

Application NDA022306 (NDA)

20132 events

FDAJun 27

Naftin — NAFTIN

Application NDA204286 (NDA)

FDAJun 27

Naftin — NAFTIN

Application NDA204286 (NDA)

20142 events

FDAOct 22

Betapace — SOTYLIZE

Application NDA205108 (NDA)

FDAOct 15

Esbriet — ESBRIET

Application NDA022535 (NDA)

20171 event

FDAJan 11

Esbriet — ESBRIET

Application NDA208780 (NDA)

20241 event

FDADec 12

Zanaflex — ONTRALFY

Application NDA216190 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)